K-STREET TRACKER
FOLLOW THE MONEY INTO THE SWAMP
Every federal lobbying filing tagged with a public-company ticker — who is spending, which firms they hire, and which members trade right around the filing.
Filings tracked
19,882
thru 2026-05-08
Total reported $
$2.7B
disclosed lobbying
Distinct clients
2,220
paying companies
Tickers targeted
1,207
public companies
💸 Top Spending Clients
| # | Client | Filings | Total $ |
|---|---|---|---|
| 1 |  PFIZER INC.PFE | 47 | $46.8M |
| 2 |  GENERAL MOTORS COMPANYGM | 61 | $46.8M |
| 3 |  META PLATFORMS INC. AND VARIOUS SUBSIDIARIESMETA | 12 | $44.9M |
| 4 | VISA INC.V | 45 | $37.7M |
| 5 |  AMAZON.COM SERVICES LLCAMZN | 36 | $32.8M |
| 6 |  LOCKHEED MARTIN CORPORATIONLMT | 73 | $29.0M |
| 7 |  FEDEX CORPORATIONFDX | 69 | $27.8M |
| 8 |  ELI LILLY AND COMPANYLLY | 56 | $27.1M |
| 9 |  ALTRIA CLIENT SERVICES LLCMO | 142 | $25.2M |
| 10 |  AMGEN INCAMGN | 19 | $24.9M |
| 11 |  COMCAST CORPORATIONCMCSV | 179 | $24.7M |
| 12 |  MERCK & CO INCMRK | 14 | $24.0M |
| 13 |  SOUTHERN COMPANYSO | 53 | $23.9M |
| 14 |  GOOGLE CLIENT SERVICES LLCGOOGL | 79 | $22.6M |
| 15 |  APPLE INCAAPL | 9 | $22.1M |
| 16 |  T-MOBILE USA INC.TMUS | 121 | $21.0M |
| 17 |  UNITEDHEALTH GROUP INCUNH | 19 | $20.4M |
| 18 |  VERIZON COMMUNICATIONS INC AND VARIOUS SUBSIDIARIESVZ | 40 | $20.1M |
| 19 |  OCCIDENTAL PETROLEUM CORPORATIONOXY | 30 | $19.7M |
| 20 |  MICROSOFT CORPORATIONMSFT | 103 | $18.8M |
| 21 |  QUALCOMM INCORPORATEDQCOM | 40 | $17.2M |
| 22 |  GENERAL DYNAMICS CORPGD | 11 | $17.0M |
| 23 |  BOEING COMPANYBA | 23 | $16.9M |
| 24 | THE CIGNA GROUP AND SUBSIDIARIES (FORMERLY CIGNA CORPORATION AND SUBSIDIARIES)CI | 13 | $16.9M |
| 25 |  ORACLE CORPORATIONORCL | 58 | $16.7M |
🎯 Top Lobbied Tickers
| # | Ticker | Filings | Total $ |
|---|---|---|---|
| 1 | META Meta Platforms Inc. | 129 | $50.2M |
| 2 | PFE Pfizer Inc. | 87 | $48.6M |
| 3 | GM General Motors Company | 103 | $48.4M |
| 4 | V Visa Inc. | 46 | $37.7M |
| 5 | AMZN Amazon.com Inc. | 80 | $35.3M |
| 6 | LMT Lockheed Martin Corporation | 88 | $29.4M |
| 7 | FDX FedEx Corporation | 82 | $28.3M |
| 8 | LLY Eli Lilly and Company | 83 | $28.1M |
| 9 | AMGN Amgen Inc. | 95 | $28.0M |
| 10 | MRK Merck & Co. Inc. | 92 | $27.5M |
| 11 | AAPL Apple Inc. | 64 | $26.8M |
| 12 | GOOGL Alphabet Inc. Class A | 123 | $26.6M |
| 13 | MO | 164 | $26.2M |
| 14 | SO Southern Company | 108 | $26.1M |
| 15 | UNH UnitedHealth Group Inc. | 67 | $23.9M |
| 16 | VZ Verizon Communications Inc. | 116 | $23.8M |
| 17 | TMUS | 159 | $22.7M |
| 18 |  CHTR | 137 | $22.6M |
| 19 | GD General Dynamics Corporation | 127 | $22.5M |
| 20 |  TAT&T Inc. | 134 | $21.6M |
| 21 | ORCL Oracle Corporation | 132 | $20.6M |
| 22 | CMCSA Comcast Corporation | 141 | $20.4M |
| 23 | CI The Cigna Group | 64 | $19.9M |
| 24 | OXY Occidental Petroleum Corporation | 36 | $19.9M |
| 25 | MSFT Microsoft Corporation | 122 | $19.2M |
🆕 Filtered Filings · AZN
clear filters| Date | Ticker | Client | Registrant | Amount | Issue |
|---|---|---|---|---|---|
| 2026-04-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | $2.3M | CMMI GENEROUS Demo Medicare Part B ASP compliance FDA modernization policy Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language) BIOSECURE Act implementation Issues related to the Medicare title in the One Big Beautiful Bill Act Issues related to the IRA definition of a drug for purposes of price negotiation selection Duplicate discounts as required by IRA Issues related to direct-to-consumer drug delivery policy options Issues related to expanding/amending the orphan drug exclusion in IRA Issues related to pharmacy benefit manager (PBM) reform Issues related to mitigation of 340B Issues related to 340B Rebate Model Pilot Program for IRA compliance Issues related to next generation propellant and PFAS Issues related to the US manufacturing of pharmaceuticals Issues related to the price and manufacture of inhaled medicines Issues related to environmental sustainability Issues related to the development of novel th |
| 2026-04-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | $80K | Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. Education about 340b program. |
| 2026-04-20 | AZN | ASTRAZENECA | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues Medicare and Medicaid drug and coverage issues, orphan drugs IRA, drug pricing in federal programs, orphan drug issues, oncology, transparency |
| 2026-04-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | TODD STRATEGY GROUP | $80K | 340B Program. Home Infusion for Part B Products. S.864: HELP Copays Act. Medicare Reimbursement for New Technologies. Pediatric Priority Review Voucher Program. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672: Maintaining Investments in New Innovation Act. H.R.946: ORPHAN Cures Act. Prescription drug pricing policy. |
| 2026-04-18 | AZN | ASTRAZENECA | TIBER CREEK GROUP | $80K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. Issues related to the 340B Program - Public Health Service Act (PL 78-410). |
| 2026-01-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | $670K | HR 1, One Big Beautiful Bill Act. Issues related to the Medicare title in the One Big Beautiful Bill Act HR 946/S 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act HR 1262/ S 932, Give Kids A Chance Act HR 4132/S 2027, Prescription Information Modernization Act BIOSECURE Act H.R.6166, the Lowering Drug Costs for American Families Act Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language); consideration of small molecule drugs, biologics, and genetically targeted technologies; duplicate discounts as required by IRA; Policies related to the definition of a qualifying single source drug under the IRA; Issues related to the IRA definition of a drug for purposes of price negotiation selection; Issues related to expanding/amending the orphan drug exclusion in IRA Issues related to pharmacy benefit manager (PBM) reform; Policies related to 340B rebate model for IRA compliance; Issues related to mit |
| 2026-01-20 | AZN | ASTRAZENECA | TIBER CREEK GROUP | $90K | Issues related to the 340B Program - Public Health Service Act (P.L. 78-410). Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Pricing reform; Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. |
| 2026-01-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | $80K | Issues around drug pricing. Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. |
| 2026-01-20 | AZN | ASTRAZENECA | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues Medicare and Medicaid drug and coverage issues, orphan drugs IRA, drug pricing in federal programs, orphan drug issues, oncology, transparency |
| 2026-01-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | TODD STRATEGY GROUP | $80K | 340B Program. Home Infusion for Part B Products. S.864 - HELP Copays Act. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. H.R.1672 - Maintaining Investments in New Innovation Act. H.R.946 - ORPHAN Cures Act. Prescription drug pricing policy. |
| 2025-10-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | $80K | Public Law 119-21: One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. |
| 2025-10-20 | AZN | ASTRAZENECA PHARMACEUTICALS LP | TODD STRATEGY GROUP | $80K | 340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. |
| 2025-10-19 | AZN | ASTRAZENECA | TIBER CREEK GROUP | $90K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. Issues related to the 340B Program - Public Health Service Act (P.L. 78-410). |
| 2025-10-17 | AZN | ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | $1.4M | E-labeling (allowing health care providers to receive prescribing information for drugs electronically rather than in paper form from manufacturers) Issues related to increasing production of US manufacturing HR 1, One Big Beautiful Bill Act. Issues related to the Medicare title in the One Big Beautiful Bill Act HR 946/S 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act HR 1262/ S 932, Give Kids A Chance Act HR 4132/S 2027, Prescription Information Modernization Act BIOSECURE Act Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language); consideration of small molecule drugs, biologics, and genetically targeted technologies; duplicate discounts as required by IRA; Policies related to the definition of a qualifying single source drug under the IRA; Issues related to the IRA definition of a drug for purposes of price negotiation selection; Issues related to expanding/amending the orphan drug ex |
| 2025-10-16 | AZN | ASTRAZENECA | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues Medicare and Medicaid drug and coverage issues, orphan drugs IRA, drug pricing in federal programs, orphan drug issues, oncology, transparency |
| 2025-10-14 | AZN | ASTRAZENECA PHARMACEUTICALS LP | TODD STRATEGY GROUP | $0 | 340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. 340B Program. Home Infusion for Part B Products. Medicare Reimbursement for New Technologies. General issues related to rare disease and orphan drugs. Diagnostics for patients with rare disease. Multi-Cancer Early Detection. |
| 2025-07-21 | AZN | ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | $1.8M | HR 1, One Big Beautiful Bill Act HR 946/S 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act HR 1262/ S 932, Give Kids A Chance Act HR 1503/S 2916, Prescription Information Modernization Act Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language); consideration of small molecule drugs, biologics, and genetically targeted technologies; duplicate discounts as required by IRA; Policies related to the definition of a qualifying single source drug under the IRA; Issues related to the IRA definition of a drug for purposes of price negotiation selection; Issues related to expanding/amending the orphan drug exclusion in IRA Orphan drugs and diseases Education to Hill staff on next generation propellant and PFAS Issues related to pharmacy benefit manager (PBM) reform; Policies related to 340B rebate model for IRA compliance; Reforms to the 340B program; Issues related to mitigation of 340B Issues relat |
| 2025-07-19 | AZN | ASTRAZENECA | TIBER CREEK GROUP | $90K | Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946/S. 1862 - ORPHAN Cures Act. |
| 2025-07-18 | AZN | ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | $80K | H.R.1 - One Big Beautiful Bill Act, as it relates to H.R.946 - Orphan Cures Act. |
| 2025-07-16 | AZN | ASTRAZENECA | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues Medicare and Medicaid drug and coverage issues, orphan drugs IRA, 340B, orphan drug issues, oncology, transparency |
| 2025-04-21 | AZN | ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | $1.2M | H.R.946 - Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act HR 1262/ S 932, Give Kids A Chance Act Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language) Issues related to Inflation Reduction Act (IRA) consideration of small molecule drugs, biologics, and genetically targeted technologies Issues related to expanding/amending the orphan drug exclusion in IRA Issues related to pharmacy benefit manager (PBM) reform Issues related to e-labeling Issues related to the price and manufacture of inhaled medicines Issues related to the IRAs drug price negotiation program Issues related to drug pricing Issues related to the US manufacturing of pharmaceuticals Issues related to importation of drugs Issues related to FDA Orange Book patent listings Issues related to environmental sustainability Issues related to FDA modernization Policies related to international reference pricing for pharmaceuticals Policies |
| 2025-04-21 | AZN | ASTRAZENECA PHARMACEUTICALS LP | PRIME POLICY GROUP | $0 | |
| 2025-04-18 | AZN | ASTRAZENECA | TIBER CREEK GROUP | $90K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Medicare Part D and Part B Pricing Reform; Issues related to the Medicaid Drug Rebate Program (MDRP); Issues related to H.R. 946 - ORPHAN Cures Act. |
| 2025-04-18 | AZN | ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | $80K | Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.946 - ORPHAN Cures Act. Issues related to insurance coverage of specialty treatments. |
| 2025-04-15 | AZN | ASTRAZENECA | TARPLIN, DOWNS & YOUNG, LLC | $80K | federal budget issues Medicare and Medicaid drug and coverage issues IRA, 340B, orphan drug issues, oncology, transparency |
| 2025-01-21 | AZN | ASTRAZENECA PHARMACEUTICALS LP | ASTRAZENECA PHARMACEUTICALS LP | $640K | H.R. 5539/S. 3131, Optimizing Research Progress Hope and New Cures (ORPHAN Cures) Act H.R.7085 BioSecure Act; Issues related to the BIOSECURE Act and US manufacturing of pharmaceuticals HR 3433/S 2897, Give Kids A Chance Act Implementation of the Inflation Reduction Act (IRA) -- with specific focus on drug negotiation (orphan drug exemption language) Issues related to expanding/amending the orphan drug exclusion in IRA Issues related to the price and manufacture of inhaled medicines Issues related to the IRAs drug price negotiation program Issues related to importation of drugs Issues related to drug pricing Issues related to RSV monoclonal antibody manufacture and distribution Issues related to FDA proposed regulation of lab developed tests Issues related to pharmacy benefit managers (PBM) reform Issues related to FDA Orange Book patent listings Issues related to COVID vaccine access and reimbursement Issues related to COPD patient access through CMMI demonstration models General issu |
| 2025-01-21 | AZN | ASTRAZENECA PHARMACEUTICALS LP | W STRATEGIES, LLC | $80K | Implementation of H.R.5376 - Inflation Reduction Act of 2022 and potential reforms involving the treatment of orphan drugs. H.R.5539 - ORPHAN Cures Act. H.R.10545 - American Relief Act, 2025 as it relates to PBM reform. Issues related to about insurance coverage of specialty treatments. |
| 2025-01-19 | AZN | ASTRAZENECA | TIBER CREEK GROUP | $60K | Issues related to implementation of drug pricing and reimbursement of prescription drugs provision in The Inflation Reduction Act of 2022 (PL 117-169); Issues relating to Medicare Part D and Part B Pricing Reform; Issues relating to the Medicaid Drug Rebate Program (MDRP); H.R. 5539/S. 3131 - ORPHAN Cures Act. |
| 2025-01-19 | AZN | ASTRAZENECA PHARMACEUTICALS LP | PRIME POLICY GROUP | $60K |